Citigroup
ENGN icon

Citigroup’s enGene Therapeutics ENGN Stock Holding History

Citigroup’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$674 Sell
99
-1,589
-94% -$14.1K ﹤0.01% 5514
2025
Q4 		$15.2K Buy
1,688
+1,687
+168,700% +$13.5K ﹤0.01% 4935
2025
Q3 		$7 Buy
+1
New +$5 ﹤0.01% 5960

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Citigroup's ENGN Position: Q1 2026 in Review

Citigroup reduced its enGene Therapeutics (ENGN) stake by 94% in Q1 2026, selling an estimated $14.1K and leaving 99 shares worth $674. The position accounts for ﹤0.01% of the portfolio, ranked #5514.

Citigroup first reported a position in ENGN in Q3 2025 and has held it in 3 quarters since. The position peaked at $15.2K in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Citigroup held 99 shares of enGene Therapeutics worth $674 as of Q1 2026.
  • Citigroup sold 1,589 enGene Therapeutics shares in Q1 2026, an estimated $14.1K.
  • enGene Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5514 holding.
  • Citigroup first reported a position in enGene Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Citigroup's enGene Therapeutics position peaked at $15.2K in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.